Literature DB >> 15072449

Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.

Elisabetta Donzelli1, Maria Carfì, Mariarosaria Miloso, Alberto Strada, Stefania Galbiati, Martine Bayssas, Genevieve Griffon-Etienne, Guido Cavaletti, Maria Grazia Petruccioli, Giovanni Tredici.   

Abstract

The main dose-limiting side effect of cancer treatment with platinum compounds is peripheral neurotoxicity. To investigate the intracellular mechanisms of platinum drugs neurotoxicity we have studied the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. Both platinum compounds are toxic causing cellular death by inducing apoptosis but oxaliplatin is less neurotoxic than cisplatin. The study of the proteins involved in the intracellular transduction pathways that may cause apoptotic death, revealed a very similar pattern of changes after exposure to cisplatin or oxaliplatin. In particular, as demonstrated by densitometric analysis, after exposure to both platinum compounds the total amount of the anti-apoptotic protein Bcl-2 was significantly reduced. Conversely, the amount of the pro-apoptotic protein p53 significantly increased. Caspases 3 and 7 were activated, but their activation was a late event, indicating a secondary role in the apoptotic process. Among the mitogen activated protein kinases, only the p38 protein was activated (phosphorylated) early enough to have a possible role in inducing apoptosis, possibly through p53 stabilization. The results of the present study and the data of the literature demonstrate that the ways in which cisplatin and oxaliplatin are neurotoxic are very similar and include not only DNA damage, but also the modulation of specific molecules involved in regulating the cellular equilibrium between apoptotic death and the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072449     DOI: 10.1023/b:neon.0000021787.70029.ce

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

1.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.

Authors:  F Grolleau; L Gamelin; M Boisdron-Celle; B Lapied; M Pelhate; E Gamelin
Journal:  J Neurophysiol       Date:  2001-05       Impact factor: 2.714

Review 2.  The proto-oncogene Bcl-2 and its role in regulating apoptosis.

Authors:  G Kroemer
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

Review 3.  The role of p53 in human cancer.

Authors:  D Malkin
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

5.  Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7.

Authors:  M Germain; E B Affar; D D'Amours; V M Dixit; G S Salvesen; G G Poirier
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

6.  The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase beta on templates with platinum-DNA adducts.

Authors:  A Vaisman; M W Warren; S G Chaney
Journal:  J Biol Chem       Date:  2001-03-20       Impact factor: 5.157

7.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

Authors:  J T Reardon; A Vaisman; S G Chaney; A Sancar
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

8.  Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.

Authors:  Tal Peleg-Shulman; Yousef Najajreh; Dan Gibson
Journal:  J Inorg Biochem       Date:  2002-07-25       Impact factor: 4.155

Review 9.  Oxaliplatin: a review of preclinical and clinical studies.

Authors:  E Raymond; S G Chaney; A Taamma; E Cvitkovic
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

10.  Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells.

Authors:  G Nicolini; R Rigolio; A Scuteri; M Miloso; D Saccomanno; G Cavaletti; G Tredici
Journal:  Neurochem Int       Date:  2003-04       Impact factor: 3.921

View more
  23 in total

1.  Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.

Authors:  Germán Morís; Renee Ribacoba; Carmen González
Journal:  J Neurol       Date:  2007-03-04       Impact factor: 4.849

2.  Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone.

Authors:  Changxin Huang; Yiqian Jiang; Guangliang Duan; Zhaoyang Li; Lingzhi Chen; Xuechun Wang
Journal:  J Neurooncol       Date:  2012-03-24       Impact factor: 4.130

Review 3.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

4.  Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line.

Authors:  Muhammed Sait Ertugrul; Hayrunnisa Nadaroglu; Ozge Balpinar Nalci; Ahmet Hacimuftuoglu; Azize Alayli
Journal:  Cytotechnology       Date:  2020-10-23       Impact factor: 2.058

5.  Protective effects of acetyl-L-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma.

Authors:  Zekiye Sultan Altun; Dilek Güneş; Safiye Aktaş; Zübeyde Erbayraktar; Zübeyde Erbayrktar; Nur Olgun
Journal:  Neurochem Res       Date:  2009-10-23       Impact factor: 3.996

6.  p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses.

Authors:  J Jefferson P Perry; Rodney M Harris; Davide Moiani; Arthur J Olson; John A Tainer
Journal:  J Mol Biol       Date:  2009-06-06       Impact factor: 5.469

7.  Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.

Authors:  Catherine G Lam; Wayne L Furman; Chong Wang; Sheri L Spunt; Jianrong Wu; Percy Ivy; Victor M Santana; Lisa M McGregor
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

8.  Induction of apoptosis on ovarian adenocarcinoma cells, A2780 by tricyclohexylphosphanegold (I) mercaptobenzoate derivatives via intrinsic and extrinsic pathways.

Authors:  Kok Pian Ang; Pit Foong Chan; Roslida Abd Hamid
Journal:  J Biol Inorg Chem       Date:  2021-09-03       Impact factor: 3.358

9.  P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach.

Authors:  France Massicot; Guillaume Hache; Ludivine David; Dominique Chen; Charlotte Leuxe; Laure Garnier-Legrand; Patrice Rat; Olivier Laprévote; François Coudoré
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

10.  Antiproliferative activity exerted by tricyclohexylphosphanegold(I) n-mercaptobenzoate against MCF-7 and A2780 cell lines: the role of p53 signaling pathways.

Authors:  Kok Pian Ang; Pit Foong Chan; Roslida Abd Hamid
Journal:  Biometals       Date:  2020-11-16       Impact factor: 2.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.